Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC-1: Electroporation Potentiated Immunotherapy in Liver Metastatic Pancreatic Cancer
NCT04835402Phase 2Active, not recruiting
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in pancreatic cancer (PC). Started May 2021; status: active, not recruiting.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04835402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835402.